<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene Q493R literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.Q493R</span> literature reference collection</h1>
<div class="effect_section"><h2 id="antibody_epitope_effects">Antibody epitope effects</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. <br/> (<a href="https://doi.org/10.1101/2020.11.03.367391" class="lit_link">Gaebler et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Somewhat resistent to some class 1 (Spike 'up') antibodies tested.<br/>Mix of non- to strongly resistent in class 2 antibodies tested. (<a href="https://doi.org/10.1101/2021.01.15.426911" class="lit_link">Wang et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Massive reduction in binding efficiency vs wild type for mAbs CB6/LY-CoV16 and LY-CoV555.<br/> (<a href="https://doi.org/10.1126/science.abf4830" class="lit_link">Rappazzo et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_escape">Convalescent plasma escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Escape mutant found after in passage in plasma pool of 26 convalescents obtained mean 1.3 months post infection.<br/> (<a href="https://doi.org/10.1101/2021.08.06.455491" class="lit_link">Schmidt et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="monoclonal_antibody_serial_passage_escape">Monoclonal antibody serial passage escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Strong positive selection (up to 37% of supernatant sequences) after two rounds of C135 monoclonal antibody passage, overall 76% switch away from Q493 to K or R (<a href="https://doi.org/10.1101/2020.07.21.214759" class="lit_link">Weisblum et al. (2020)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> The engineered mutation cause 10-fold or more increase in the disassociation constant with C144, C002 and C121 monoclonal antibodies vs. wild type Spike protein RBD domain AAs.<br/> (<a href="https://doi.org/10.1038/s41586-020-2852-1" class="lit_link">Barnes et al. (2020)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab) (<a href="https://doi.org/10.1101/2021.02.17.431683" class="lit_link">Starr et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Class 2 mAb C627 modestly selected for the emergence of this mutation in vitro.<br/> (<a href="https://doi.org/10.1101/2021.01.15.426911" class="lit_link">Wang et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
